Prostate Cancer
VIDEO: Cardiac events can be more likely with androgen deprivation therapy
In this video, Alicia Morgans, MD, discusses a study on the association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer.
Delaying therapy for localized prostate cancer does not affect long-term survival
Men with localized prostate cancer exhibited low risk for disease-specific mortality regardless of their assigned treatment, according to study results published in The New England Journal of Medicine.
Model increases odds of timely prostate cancer germline testing, but disparities persist
Germline genetic testing has become an increasingly valuable tool for patients with various malignancies, including prostate cancer.
VIDEO: Patients with prostate cancer suffer testosterone recovery delays
In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses an abstract that looked at randomized trials of prostate cancer patients receiving radiation therapy and androgen deprivation.
Rates of active surveillance for low-risk prostate cancer rise, ‘remain suboptimal’
Despite an increase in national, community-based rates of active surveillance for management of low-risk prostate cancer, the guideline-endorsed strategy remains underutilized, according to research published in JAMA Network Open.
Optimizing CV health behaviors may lower risk for CVD and cancer
Improvement in the American Heart Association’s Life’s Simple 7 CV health score was associated with lower risk for cancer and CVD during nearly 25 years of follow-up, researchers reported.
All-cause, CVD mortality highest in Black patients among those with cancer
Researchers observed significant racial disparities in all-cause and CVD mortality among adults with cancer, with wider gaps found among patients younger than 55 years, according to a study published in JACC: CardioOncology.
Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations
SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.
Poor control of CVD risk factors common in men with prostate cancer
Men with prostate cancer are likely to have poor control of modifiable CV risk factors, according to study findings published in JACC: CardioOncology.
Plant-based diet may reduce risk for prostate cancer progression
SAN FRANCISCO — Men with the greatest adherence to plant-based diets exhibited reduced risk for prostate cancer progression or recurrence compared with men with the lowest adherence, findings presented at ASCO Genitourinary Cancers Symposium showed.